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Abstract: Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel
disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response to
anti-TNF therapy, considered as the need for dose intensification (DI), DI effectiveness and the
possible variables influencing its requirements. Bibliographical searches were performed. Selection:
prospective and retrospective studies assessing DI in Crohn’s disease and ulcerative colitis patients
treated for at least 12 weeks with an anti-TNF drug. Exclusion criteria: studies using anti-TNF as
a prophylaxis for the postoperative recurrence in Crohn’s disease or those where DI was based on
therapeutic drug monitoring. Data synthesis: effectiveness by intention-to-treat (random effects
model). Data were stratified by medical condition (ulcerative colitis vs. Crohn’s disease), anti-TNF
drug and follow-up. Results: One hundred and seventy-three studies (33,241 patients) were included.
Overall rate of the DI requirement after 12 months was 28% (95% CI 24–32, I2 = 96%, 41 studies) in
naïve patients and 39% (95% CI 31–47, I2 = 86%, 18 studies) in non-naïve patients. The DI requirement
rate was higher both in those with prior anti-TNF exposure (p = 0.01) and with ulcerative colitis
(p = 0.02). The DI requirement rate in naïve patients after 36 months was 35% (95% CI 28–43%;
I2 = 98%; 18 studies). The overall short-term response and remission rates of empirical DI in naïve
patients were 63% (95% CI 48–78%; I2 = 99%; 32 studies) and 48% (95% CI: 39–58%; I2 = 92%;
25 studies), respectively. The loss of response to anti-TNF agents—and, consequently, DI—occurred
frequently in inflammatory bowel disease (approximately in one-fourth at one year and in one-third
at 3 years). Empirical DI was a relatively effective therapeutic option.
Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; anti-TNF-α; loss of
response; dose intensification
1. Introduction
Biologic therapies have become the mainstay of treatment in inflammatory bowel
disease (IBD). Antibodies targeting tumor necrosis factor-alpha (anti-TNF) have become
essential in the armamentarium for the treatment of both ulcerative colitis (UC) and Crohn’s
disease (CD). TNF is a key proinflammatory cytokine that plays an important role in several
autoimmune disorders, including IBD. Elevated stool and mucosal TNF concentrations in
UC and CD patients have been shown to correlate with the disease activity [1]. Anti-TNF
drugs operate via a multitude of mechanisms: they bind and clear soluble TNF but, also,
cell-bound TNF, inducing cytotoxicity on immune cells, like T-cell apoptosis [2]. They are
effective at inducing symptom relief, disease remission and mucosal healing and reducing
the need for surgery and hospitalizations among patients with moderate-to-severe IBD.
The current clinical guidelines recommend anti-TNF agents for patients who are refractory
to other treatments [3–6].
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However, a considerable proportion of these patients does not respond to induction
therapy (primary nonresponse) or lose response over time (secondary nonresponse or
loss of response, LOR). In patients who experience LOR to a particular anti-TNF agent,
dose escalation or intensification (DI), either by increasing the dose or decreasing the
dosing intervals, is commonly used as a rescue strategy to regain the therapeutic effect.
Nevertheless, the exact incidence and chronology of this intensification, and its efficacy, are
still not well-known.
The aim of this systematic review was to evaluate the incidence of LOR (defined as
the need for DI) over time and DI efficacy in regaining both the response and remission
in inflammatory bowel disease. The secondary objectives were to identify the possible
variables (baseline medical condition, anti-TNF therapy and time of follow-up) influencing
the DI requirement and its efficacy.
2. Materials and Methods
2.1. Literature Search and Study Selection
Bibliographic searches were performed in four electronic databases (Medline, Embase,
Cochrane Library CENTRAL and CINAHL) from inception up to January 2020. The
search strategy (with corresponding keywords in all fields) was: “(inflammatory bowel
disease OR Crohn’s disease OR ulcerative colitis) AND (infliximab OR adalimumab OR
certolizumab OR golimumab OR antiTNF OR anti-TNF) AND (intensification OR escalation
OR optimization OR optimisation)”. Additional hand searches were performed by the cross-
referencing of eligible studies in order to identify further relevant publications. Abstracts
were screened to discard duplicates. When the literature search yielded two or more studies
by the same author assessing the same populations, only the most recent one was chosen,
irrespective of the time interval, as it was assumed the latter published would include the
most comprehensive and complete data.
The process of study selection is depicted in a flow diagram following the PRISMA
statement [7]. The present systematic review was registered in PROSPERO (CRD42017073757).
The selection process, data extraction and analyses were performed by two authors (LG
and OPN) independently. If discrepancies occurred, consensus was reached by a third
reviewer (JPG). The corresponding authors of the studies without sufficient data were
contacted for additional information.
2.2. Selection Criteria
Prospective and retrospective studies assessing the LOR to anti-TNF therapy, consid-
ered as the need for DI in patients with CD and UC treated for at least 12 weeks with an
anti-TNF drug, were selected for inclusion. There were no language restrictions.
Articles in which an anti-TNF was used as the prophylaxis for postoperative recurrence
in CD and those where DI was based during therapeutic drug monitoring were excluded.
Systematic or narrative reviews, case studies and congress abstracts were excluded from
this systematic review.
2.3. Data Extraction and Quality Assessment
A predefined, pre-piloted data extraction form was used to collect the data. The variables
recorded were: year of publication; study design (prospective or retrospective); age of the
study population (adults ≥ 18 years and children < 18 years); type of inflammatory bowel
disease (UC or CD); therapeutic regimens (infliximab (IFX), adalimumab (ADA), certolizumab-
pegol, and golimumab); previous anti-TNF treatments (naïve or non-naïve); length of follow-
up in months; sample size; and outcome measures (DI requirement and DI efficacy).
The Cochrane risk of bias tool [8] was used to assess the quality of the randomized
controlled trials, as they were considered the most reliable method of outcome assessment.
The decision was reached post-hoc after performing an exploratory mapping review and
confirming the wide range of observational studies in terms of the number and design
available in the literature responding to our topic of interest.
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2.4. Data Synthesis and Statistical Analysis
All analyses were preplanned a priori. The primary outcomes were the DI requirement
measured as the number of patients receiving a DI out of the total of patients studied and
DI efficacy in the short term as the number of patients responding out of the total of patients
receiving a DI, expressed as the response rate with its standard error. These outcomes
were thereafter combined using the inverse variance method, providing 95% confidence
intervals (CIs). The statistical significance threshold was set at p-value < 0.05. A random
effects model was used.
The study heterogeneity was analyzed using the I2 statistic: according to the I2 values,
the heterogeneity was considered as: not important (I2 < 40%), moderate (40–75%) and
considerable (>75%). Such interpretations also adjusted for the magnitude of the effect
and/or the strength of the evidence given (i.e., p-value < 0.1 of the χ2 test). Begg’s funnel
plot [9] was used to estimate the possibility of publication bias.
Post-hoc sensitivity analyses were performed for each meta-analysis subgroup by
excluding those studies that were identified as potentially introducing a critical risk of bias
that could likely modify the outcome.
Data were analyzed using the Review Manager program (version 5.2).
3. Results
A total of 173 studies (including 33,241 patients) met the inclusion criteria and were
finally included in the systematic review and meta-analysis (Figure 1).
Figure 1. PRISMA flowchart of the screening and selection.
The description of each included study is summarized in Table 1.
There were six randomized, placebo-controlled trials (RCTs) [10–15], 48 prospective
open-label observational trials and 119 retrospective studies.
A total of 157 studies assessed the need for DI; the response rate was evaluated in
52 studies, and the remission rate was reported in 33 studies.
One hundred and one studies focused on naïve patients, and 29 evaluated non-naïve
patients, while 50 studies included both naïve and non-naïve patients in their assessments.
In six studies, prior anti-TNF exposure was not reported. One hundred and seven studies
reported the data from IFX users and 92 from ADA users. Only five studies included
patients receiving golimumab [16–20], and four studies evaluated patients receiving cer-
tolizumab [21–24]; thus, a meta-analysis was not performed.
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Table 1. Studies included in the meta-analysis.















1 Afif 2009 [25] P A UC ADA Naïve andnon-naïve 6 7 20 35
2 Albisi 2019 [26] R C CD ADA Non-naïve 12 3 44 7 ID Response 2 3 67
3 Armuzzi 2013 [27] R A UC ADA Naïve andnon-naïve 12 31 88 35
4 Assa 2013 [28] R C UC+CD IFX+ADA - 20 10 102 10
5 Baert 2014 [29] R A UC ADA Non-naïve 12 22 73 30
6 Baert 2013 [30] R A CD ADA Naïve andnon-naïve 14 208 605 34 RI Response 139 208 67
CD ADA Naïve 14 40 208 19
CD ADA Non-naïve 14 164 365 45
7 Baki 2015 [31] R A UC IFX Naïve andnon-naïve 5 26 54 48
UC ADA Naïve andnon-naïve 4 17 37 46
8 Balint 2018 [32] P A UC IFX Naïve 12 20 61 33
9 Balint 2016 [33] P A+C UC ADA Naïve andnon-naïve 12 13 73 18
10 Bhalme 2013 [34] R A CD IFX Naïve 13 4 76 5
ADA Naïve 11 2 15 13
ADA Non-naïve 11 9 39 23
ADA Naïve andnon-naïve 11 11 54 20
11 Black 2016 [35] R A UC ADA Naïve 12 66 155 43
ADA Non-naïve 12 17 36 47
12 Bor 2017 [36] R A CD IFX Naïve andnon-naïve - 14 48 29 ID Remission 3 14 21
13 Bortlik 2013 [37] R A CD IFX Naïve andnon-naïve 24 6 84 7
14 Bossuyt 2019 [38] P A UC GOL Naïve andnon-naïve 6 8 91 9
15 Bouguen 2015 [39] P A CD ADA Naïve andnon-naïve - Response 23 42 55
Remission 14 42 33
16 Bramuzzo 2019 [40] R C UC+CD IFX Naïve 12 44 172 26
17 Brandes 2019 [41] R A UC+CD ADA Naïve andnon-naïve 12 76 502 15
18 Bultman 2012 [42] P A CD ADA Naïve 12 23 49 47 - Response 20 46 43
CD ADA Non-naïve 12 23 73 31.5
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19 Cameron 2015 [43] R C UC+CD IFX Naïve 23 23 72 32
UC+CD ADA Naïve andnon-naïve 14 19 29 66
20 Casanova 2019 [21] R A UC+CD IFX+ADA+CZP Non-naïve 18 230 1122 20.5 RI or ID Remission 161 230 42
21 Casellas 2015 [44] P A CD ADA Naïve andnon-naïve 36 3 28 11
22 Castaño 2015 [45] R A CD ADA Naïve 12 9 46 20 RI Remission 3 9 33
23 Caviglia 2007 [46] R A UC IFX - 24 0 10 0
CD IFX - 24 3 40 7.5
24 Cesarini 2014 [47] R A UC IFX Naïve 24 RI or ID Response 37 41 90
Remission 19 41 46
RI Response 24 26 92
Remission 9 26 35
ID Response 13 15 87
Remission 10 15 67
25 Chaparro 2011 [48] R A CD IFX Naïve 41 127 309 RI + ID Response 122 127 96
Remission 71 127 56
26 Chaparro 2012 [49] R A CD IFX Naïve 22 33 197 17 - Response 26 33 79
Remission 11 33 33
27 Cheng, 2017 [50] R C UC IFX Naïve 24 60 113 53 RI or ID Response 36 60 60
CD IFX Naïve 24 19 35 54 RI or ID Response 12 35 34
28 Choi 2014 [51] R A CD ADA Naïve 18 5 36 14
IFX Naïve 18 0 36 0
29 Choi 2017 [52] R C CD IFX Naïve 16 14 29 48 RI or ID Response 17 21 80
UC IFX Naïve 16 7 10 70
30 Church 2014 [53] R C CD IFX Naïve 21 79 157 50
31 Clark 2019 [54] R A CD IFX Non-naïve 24 10 17 59
32 Cohen 2012 [55] R A CD ADA Naïve andnon-naïve 55 31 75 41
33 Cordero 2011 [56] P A CD ADA Non-naïve 12 18 25 72
34 DeRidder 2008 [57] R C CD IFX Naïve 41 40 66 61
35 DeBruyn 2017 [58] R C CD IFX Naïve 19 102 178 57
36 D’Haens 2018 [10] P A CD IFX Naïve 12 16 40 40
37 Dignass 2019 [17] R A UC IFX Naïve 24 75 114 66
UC ADA Naïve 24 49 125 39
UC GOL Naïve 24 27 47 57
38 Dreesen 2018 [59] R A CD IFX Naïve RI, ID, RI+ID Response 65 103 63
ID Response 24 45 53
RI Response 33 45 73
RI + ID Response 8 13 61
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39 Dubinsky 2016 [60] P C CD ADA Naïve andnon-naïve 12 35 93 38 RI Response 20 35 57
RI Remission 11 35 31
Naïve 12 18 51 35 RI Response 13 18 72
RI Remission 5 18 28
Non-naïve 12 17 42 40 RI Response 7 17 41
RI Remission 3 17 18
40 Dumitrescu 2015 [61] R A UC IFX Naïve RI or ID Response 87 157 55
Remission 28 157 18
41 Dupont 2016 [62] R C CD IFX Naïve - 65 187 35
42 Duveau 2016 [63] R A CD ADA Naïve andnon-naïve - 124 430 29 RI or ID Response 99 124 80
43 Echarri 2015 [64] P A CD ADA Naïve 24 12 68 18 RI Remission 9 12 75
44 Falaiye 2014 [65] R A UC+CD IFX Naïve 12 18 29 62 RI or ID Response 7 18 39
45 Fernandes 2019 [66] R A UC+CD IFX Naïve andnon-naïve 12 25 149 17
UC+CD IFX Naïve andnon-naïve 24 38 149 25.5
46 Fernández-Salazar2015 [67] R A UC IFX Naïve 38 53 144 37
47 Fiorino 2017 [68] P A+C UC+CD IFX Naïve andnon-naïve 3 74 399 16
48 Fortea-Ormaechea2011 [69] R A CD ADA
Naïve and
non-naïve 9 57 174 33
49 Frederiksen 2014 [70] R A UC+CD ADA No naïve 9 21 57 37
50 García bosch 2013 [71] R A UC ADA Naïve andnon-naïve 12 18 48 37.5 - Response 15 18 83
- Remission 8 18 44
51 Ghaly 2015 [72] R A CD IFX+ADA Naïve andnon-naïve 40 73 - Response 40 73 55
52 Gofin 2019 [73] R C CD IFX+ADA Naïve 19 18 98 18
53 Gonczi 2017 [74] P A UC+CD ADA Naïve andnon-naïve 12 22 112 20
24 33 112 29
54 Gonzaga 2009 [75] R A CD IFX Naïve 49 56 111 50
55 González Lama2008 [76] R A CD IFX Naïve 28 15 114 13 RI or ID Response 10 15 67
56 Grover 2014 [77] R C CD IFX Naïve 12 13 47 28 - Response 7 13 54
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57 Guerbau 2017 [78] P A CD IFX Naïve andnon-naïve 12 43 140 30
58 Guidi 2018 [79] P A UC+CD IFX Naïve 3 37 52 71
59 Ho 2008 [80] R A CD ADA Non-naïve 12 13 22 59
60 Ho 2009 [81] R A+C CD ADA Naïve andnon-naïve 6 24 98 24
CD ADA Naïve 12 2 10 20
CD ADA Non-naïve 12 28 88 32
CD ADA Naïve andnon-naïve 24 54 98 55
61 Hussey 2016 [82] R A UC ADA Naïve andnon-naïve 19 13 55 24
62 Hyams 2010 [83] P C UC IFX Naïve 30 11 34 33
63 Hyams 2007 [11] P C CD IFX Naïve 12 9 52 17 ID Response 5 9 56
64 Iborra 2017 [84] R A UC ADA Naïve andnon-naïve 12 93 263 35
ADA Naïve 12 21 87 24
ADA Non-naïve 12 72 176 41
65 Inokuchi 2019 [85] R A CD IFX Naïve 83 54 183 29.5
CD ADA Naïve 43 6 80 7.5
66 Juillerat 2015 [86] R A CD IFX Naïve andnon-naïve - 77 250 31
67 Juliao 2013 [87] R A UC IFX Naïve 27 4 28 14 RI Response 4 4 100
68 Kang 2016 [88] P C CD IFX Naïve 12 7 72 10
69 Karmiris 2009 [89] P A CD ADA Non-naïve 20 102 156 65 RI Response 73 102 72
70 Katz 2012 [90] R A CD IFX Naïve - RI or ID Response 123 168 73
RI Response 37 56 66
ID Response 86 112 77
71 Kelly 2017 [91] R A UC+CD IFX Naïve RI or ID Response 82 143 57
Remission 69 143 48
72 Kierkus 2015 [12] P C CD IFX Naïve 12 16 84 19
73 Kiss 2011 [92] R A CD ADA Naïve andnon-naïve 12 33 201 16
74 Knyazev 2018 [22] P A CD CRP Naïve andnon-naïve 24 3 39 8
75 Knyazev 2016 [93] R A UC IFX Naïve - 5 45 11 - Remission 4 5 80
76 Knyazev 2017 [94] P A CD ADA Naïve andnon-naïve 28 6 70 9
77 Kopylov 2011 [95] R A CD IFX Naïve RI Response 38 55 70
CD IFX Naïve ID Response 26 39 67
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78 Kunovski 2020 [96] R A UC IFX Naïve 12 43 396 11
ADA Naïve 12 34 172 20
79 Lam 2014 [97] R A CD IFX Naïve 12 34 68 50
80 Lees 2009 [98] R A+C UC+CD ADA Non-naïve 12 16 30 53
81 Lin 2012 [99] R A CD IFX Naïve 60 34 94 36 RI or ID Response 24 30 80
82 Lindsay 2013 [100] R A+C CD IFX Naïve 12 9 380 2
IFX Naïve 24 19 380 5
83 Lindsay 2017 [101] R A UC IFX+ADA 24 139 538 26
CD IFX+ADA Naïve 24 126 657 19
84 Ling 2018 [102] R C CD IFX Naïve 24 26 43 60 RI or ID Response 14 26 54
85 Llaó 2016 [103] P A UC IFX - 18 8 15 53
86 Lofberg 2012 [104] P A CD ADA Naïve andnon-naïve 5 131 945 14 RI Remission 46 131 35
87 Lopez Palacios2008 [105] R A CD ADA Non-naïve 24 6 22 27 RI Response 4 6 66
88 Ma 2015 [106] R A UC IFX Naïve 158 36 66 54
UC ADA Naïve 139 18 36 50
89 Ma 2014 [107] R A CD IFX Naïve 40 60 117 51
CD ADA Naïve 28 23 38 61
CD ADA Non-naïve 28 41 63 65
90 Ma 2016 [108] R A CD IFX+ADA Naïve 38 116 190 61
91 Ma 2014 (bis) [109] R A CD ADA Naïve andnon-naïve - - Response 74 92 80
92 Magro 2014 [110] R A CD IFX Naïve 84 55 163 34
UC IFX Naïve 84 19 52 37
93 Martineau 2017 [19] R A CD GOL Non-naïve 18 51 115 44 - Response 27 51 53
94 Merras 2016 [20] P C CD GOL Non-naïve * 1 6 17
95 Molnar 2012 [111] R A CD IFX Naïve 12 3 35 9
CD ADA Naïve 12 3 10 30
CD ADA Non-naïve 12 13 16 81
96 Moon 2015 [23] R A CD CZP Naïve andnon-naïve 26 43 358 12
97 Motoya 2018 [112] P A+C CD ADA Naïve andnon-naïve RI Response 16 28 57
CD ADA Naïve andnon-naïve RI Remission 10 28 35
ADA Naïve RI Response 6 9 67
ADA Naïve RI Remission 5 9 56
ADA Non-naïve RI Response 10 19 53
ADA Non-naïve RI Remission 5 19 26
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98 Moroi 2019 [113] R A CD IFX Naïve 36 17 62 27
ADA Naïve 36 0 7 0
99 Murthy 2015 [114] R A UC IFX Naïve 12 59 116 51
100 Narula 2016 [115] P A CD IFX Naïve 24 35 251 14
CD ADA Naïve 24 9 111 8
101 Nedelkopoulou 2018[116] R C UC IFX Naïve 20 2 10 20
102 Ng 2009 [117] P A CD ADA Non-naïve 12 2 7 29 RI Response 2 2 100
103 Nichita 2010 [118] R A CD ADA Naïve andnon-naïve 12 13 55 24 RI or ID Response 8 13 62
Remission 6 13 46
104 Nuti 2014 [119] R C CD IFX+ADA Naïve andnon-naïve 36 27 78 35
105 O’Donnell 2015 [120] R A+C CD IFX Naïve 36 133 287 46
UC IFX Naïve 36 84 125 67
106 Olivares 2019 [121] P A UC+CD ADA Naïve 18. 15 33 45
UC+CD ADA Non-naïve 18. 37 53 70
UC ADA Naïve andnon-naïve 6. 7 43 16
CD ADA Naïve andnon-naïve 6. 21 43 49
UC ADA Naïve andnon-naïve 18. 24 43 56
CD ADA Naïve andnon-naïve 20. 28 43 65
107 Orlando 2012 [122] P A CD ADA Naïve andnon-naïve 14. 15 110 14
108 Osterman 2017 [123] R A CD IFX Naïve 12 42 381 11
ADA Naive 12 16 196 8
109 Oussalah 2009 [124] R A CD ADA Non-naïve 36 7 53 13 RI Remission 6 7 86
110 Oussalah 2010 [125] R A UC IFX Naïve 18 36 80 45
111 Panaccione 2010 [126] P A CD ADA Naïve 12 71 260 27
24 105 260 40
112 Paredes 2020 [127] P A UC+CD IFX Naïve 12 2 31 6
UC+CD IFX Naïve 24 12 31 39 - Response 6 12 50
UC IFX Naïve 24 3 31 10
CD IFX Naïve 24 9 31 29
113 Pariente 2012 [128] R A UC+CD IFX Naïve RI or ID Response 27 39 69
114 Park 2016 [129] R A CD IFX Naïve 36 86 582 15
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115 Patel 2017 [130] R A CD IFX+ADA+CZP+GOL Naïve 6 640 4569 14
Naïve 12 1097 4569 24
Naïve 24 1553 4569 34
Naïve 36 1782 4569 39
UC IFX+ADA+CZP+GOL Naïve 6 272 1699 16
Naïve 12 475 1699 28
Naïve 24 680 1699 40
Naïve 36 748 1699 44
116 Paul 2013 [131] P A UC+CD IFX Naïve andnon-naïve ID Remission 30 52 58
117 Peters 2014 [132] R A CD ADA Naïve 24 45 167 27
CD ADA Non-naïve 24 135 271 50
118 Peyrin 2007 [133] P A CD ADA Non-naïve 12 6 24 25
119 Pollinger 2019 [134] R A UC ADA Naïve 12 48 154 31
120 Preda 2016 [135] R A CD IFX Naïve 36 26 129 20 - Remission 11 26 42
CD ADA Naïve 20 19 136 14 - Remission 16 19 84
121 Qazi 2016 [136] P A UC+CD IFX Naïve 24 10 75 13
122 Regueiro 2007 [137] R A CD IFX Naïve andnon-naïve 30 54 108 50 RI or ID Response 41 54 76
123 Reinisch 2013 [138] P A UC ADA Naïve 12 110 445 25
124 Renna 2016 [139] P A UC ADA Non-naïve < 6 1 16 6
125 Renna 2018 [140] R A UC ADA Naïve andnon-naïve 10 50 118 42 RI Response 23 50 46
126 Riis 2012 [141] R A CD IFX Naïve 59 10 58 17
CD ADA Naïve 36 1 19 5
127 Roblin 2014 [142] P A UC+CD ADA Naïve RI Remission 30 82 36
128 Roblin, 2016 [143] P A CD IFX Naïve andnon-naïve 20 30 119 25
129 Roblin 2015 [144] P A UC+CD IFX Naïve 20 10 93 11
130 Rostholder 2012[145] R A UC IFX Naïve 12 27 50 54 RI or ID Remission 5 27 19
131 Rubin 2012 [146] R A CD ANTI TNF - 24 531 1398 38
132 Russo 2009 [147] R A UC IFX Naïve 15 2 38 5 RI or ID Response 0 2 0
133 Rutka 2016 [148] UC ADA Naïve andnon-naïve 12 13 73 18
134 Sandborn 2007 [13] P A CD ADA Naïve 12 89 204 44 - Remission 37 89 42
135 Sandborn 2016 [149] R A UC IFX Naïve 11 166 424 39
UC ADA Naïve 11 138 380 36
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136 Sands 2004 [14] P A CD IFX Naïve 12 28 96 29 RI Response 12 21 57
137 Sartini 2018 [150] R A UC ADA Naïve andnon-naïve 24 17 32 53
CD ADA Naïve andnon-naïve 24 58 149 39
138 Sazuka 2012 [151] R A CD IFX Naïve 21 30 74 40
139 Schnitzler 2009 [152] P A CD IFX Naïve 55 218 547 40
140 Seo 2017 [153] R A CD ADA Naïve andnon-naïve 17 45 254 18
141 Seow 2010 [154] P A UC IFX Naïve 14 74 115 64 RI or ID Remission 29 74 39
142 Shapiro 2015 [155] R C UC+CD IFX Naïve 12 35 87 40 RI or ID Response 30 35 86
143 Sierra 2016 [156] R A CU ADA Naïve andnon-naïve 12 16 37 43
144 Sprakes 2012 [157] P A CD IFX Naïve 24 18 173 10
145 Srinivasan 2018 [158] R A CD IFX+ADA Naïve andnon-naïve 12 55 423 13
146 Stein 2014 [24] R A CD CZP Naïve andnon-naïve 124 10 87 11
147 Steendholt 2015 [15] P A CD IFX Naïve RI Response 19 36 53
148 Sutharsan 2013 [159] P A CD ADA Naïve RI Response 9 14 64
CD ADA Naïve Remission 8 14 57
159 Suzuki 2015 [160] P CD IFX Naïve ID Response 23 39 59
CD IFX Naïve Remission 13 39 36
150 Suzuki 2019 [161] R A CD ADA Naïve andnon-naïve 12 14 95 15 ID Remission 8 12 67
CD ADA Naïve 12 9 78 12 Remission 5 8 62.5
CD ADA Non-naïve 12 5 17 29 Remission 2 4 50
151 Suzuki 2017 [162] P A UC ADA Naïve 36 36 190 19
152 Swoger 2010 [163] R A CD ADA Naïve 12 59 118 50
153 Tajiri 2018 [164] P C CD IFX Naïve 12 5 14 36 ID Remission 3 5 60
154 Takeuchi 2019 [165] R C UC+CD IFX Naïve 12 11 17 65
UC IFX Naïve 12 4 5 80
CD IFX Naïve 12 7 12 58
155 Taxonera 2015 [166] R A UC IFX Naïve - Response 54 79 68
R A UC IFX Naïve - Remission 41 79 52
156 Taxonera 2014 [167] R A CD IFX Naïve 13 16 59 27
R A UC IFX Naïve 9 16 38 42
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157 Taxonera 2017(bis) [168] R A UC ADA Naïve 24 12 68 18 RI or ID Response 7 12 58
RI or ID Remission 2 12 17
ADA Non-naïve 24 64 116 55 RI or ID Response 26 64 41
RI or ID Remission 13 64 20
158 Taxonera 2017 [169] R A UC GOL Naïve andnon-naïve 12 31 114 27 RI or ID Response 22 31 71
159 Taxonera 2011 [170] R A UC ADA Non-naïve 12 11 30 37 RI Response 8 11 73
160 Tigue 2017 [171] R A UC IFX + ADA - 12 3 38 8
CD IFX + ADA 12 2 24 8
161 Tkacz 2014 [172] R A CD IFX Naïve 9 18 106 17
162 Tursi 2018 [173] R A UC ADA Naïve andnon-naïve 18 9 56 16
163 Vahabnezhad 2014[174] R A+C CD IFX Naïve 30 65 89 73 RI or ID Response 40 65 62
UC IFX Naïve 25 7 13 54 RI or ID Response 4 7 57
164 Vanassche 2012 [175] P A CD IFX Naïve 12 6 37 16
165 Vandevondel 2018[176] R A UC ADA
Naïve and
non-naïve 6 129 231 56 RI Response 77 129 60
166 Vatansever 2014[177] P A CD IFX+ADA - 12 3 35 9
167 Verstock 2018 [178] R A CD ADA Naïve 12 27 116 23 - Response 19 27 70
CD ADA Naïve 18 43 116 37
168 Viazis 2015 [179] P A CD IFX+ADA Naïve 28 31 132 23 RI or ID Remission 25 31 81
169 Watanabe 2014.[180] P A CD ADA
Naïve and
non-naïve 34 40 79 51 DI Response 8 8 100
Remission 6 8 75
170 West 2008 [181] R A CD ADA No naïve 12 8 30 27 RI Response 6 8 75
171 Wolf 2014 [182] P A UC ADA Naïve andnon-naïve 3 20 123 16 RI Response 9 20 45
Remission 4 20 20
172 Yamada 2014 [183] R A UC IFX Naïve 36 17 24 71 RI or ID Remission 16 17 94
173 Yokoyama 2016[184] R A CD IFX+ADA
Naïve and
non-naïve 18 8 107 7
DI: Dose intensification. R: Retrospective. P: Prospective. UC: Ulcerative colitis. CD: Crohn’s disease. IFX: Infliximab. ADA: Adalimumab. CZP: Certolizumab pegol. GOL: Golimumab. n: number of patients
undergoing dose intensification. N: total number of patients included. ID: Increase of dose. RI: Reduction of the interval of administration. n’: number of patients with a clinical response or remission after dose
intensification. N’: total number of patients undergoing dose intensification.
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3.1. Dose Intensification Requirements
3.1.1. Twelve-Month Follow-Up
Naïve vs. Non-Naïve Patients
A total of 68 studies with a median follow-up of 12 months were analyzed.
In naïve patients, the DI rates ranged from 2% (100) to 80% (165), with an overall
pooled rate of 28% (95% CI 24-32, I2 = 96%, 41 studies) (Figure 2).
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Figure 2. Dose intensification requirements after the 12-month follow-up in anti-TNF naïve and
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In non-naïve patients, the DI rate ranged from 7% (26) to 81% (111), with an overall
pooled rate of 39% (95% CI 31-47, I2 = 86%, 18 studies) (Figure 2).
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The DI requirement after the 12-month follow-up was statistically higher in non-naïve
than in naïve patients (test for subgroup differences: χ2 = 6.13, p = 0.01, I2 = 83.7%).
Anti-TNF Use by Medical Condition in Naïve Patients
The DI requirement rate after the 12-month follow-up with all the anti-TNF agent data
was statistically higher in UC than in CD patients (test for subgroup differences: χ2 = 5.29,
p = 0.02, I2 = 81.1%). No other subgroup differences were reported by the medical condition
or anti-TNF used (Table 2).
Table 2. Dose intensification rate after the 12-month follow-up by the anti-TNF agent and
medical condition.
Anti-TNF UC/CD DI Requirement(%, 95% CI) I2 (%)
Number of
Included Studies
IFX UC+CD 29 (22–36) 96 26
IFX UC 40 (24–56) 97 8
IFX CD 21 (15–28) 92 15
ADA UC+CD 28 (22–34) 93 16
ADA UC 29 (23–35) 86 6
ADA CD 28 (17–38) 94 10
Anti-TNF: anti-tumor necrosis factor. UC: ulcerative colitis. CD: Crohn’s disease. DI: dose intensification. IFX:
Infliximab. ADA: Adalimumab.
3.1.2. Thirty-Six Month Follow-Up
A total of 25 studies with a median follow-up of 36 months were analyzed. There was
only one study reporting the DI rate in non-naïve patients, and therefore, no subgroup
analysis was performed.
The DI rates in naïve patients ranged from 0% (113) to 70% (183), with an overall rate
of 35% (95% CI 28–43%, I2 = 98%, 18 studies) (Figure 3).
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months vs. 36 months) showed no statistical differences (p>0.05) in terms of 
the DI requirements in naïve patients. 
  
Figure 3. Dose intensification requirements after the 36-month follow-up in anti-TNF naïve patients.
Anti-TNF Use by Medical Condition in Naïve Patients
No statistical differences (p > 0.05) in the medical conditions or the anti-TNF drug
used were found between the subgroups (Table 3).
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Table 3. The DI rate after 36-month follow-up by the anti-TNF agent and medical condition.
Anti-TNF UC/CD DI Requirement(%, 95% CI) I2 (%)
Number of
Included Studies
IFX UC+CD 38 (30–46) 96 15
IFX UC 48 (34–62) 82 4
IFX CD 35 (26–43) 96 12
ADA UC+CD 24 (7–40) 92 4
ADA UC 34 (3–64) 92 2
ADA CD 3 (−4–11) 80 2
Anti-TNF: anti-tumor necrosis factor. UC: ulcerative colitis. CD: Crohn’s disease. DI: dose intensification. IFX:
Infliximab. ADA: Adalimumab.
3.1.3. Short-Term Follow up
A total of 17 studies with a median of three to nine months of follow-up were included.
The DI rates in naïve patients ranged from 14% (130) to 71% (79) with an overall pooled
rate of 29% (95% CI 31–37, I2 = 96%, five studies).
A subgroup analysis evaluating the follow-up time (short-term vs. 12 months vs. 36 months)
showed no statistical differences (p > 0.05) in terms of the DI requirements in naïve patients.
3.2. Dose Intensification Efficacy
3.2.1. Response Rate
The response rates ranged from 0% (147) to 96% (48) in naïve patients and from 41%
(60) to 75% (181) in non-naïve patients.
The overall rate of the short-term response to the empirical DI was 63% (95% CI:
48–78%, I2 = 99%, 32 studies) and 58% (95% CI: 47–70%, I2 = 68%, nine studies) in the
naïve and non-naïve patients, respectively (Figure 4). No statistical differences were found
between the groups (p > 0.05).
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No statistical differences were found when comparing CD vs. UC patients or the anti-
TNF drugs used (Table 4). Neither were found (p > 0.05) between different intensification
regimens (i.e., intensification of dosing vs. reduction of the interval of administration).
Table 4. Response rate by the anti-TNF agent and medical condition.
Anti-TNF UC/CD Response Rate(%, 95% CI) I2 (%)
Number of
Included Studies
IFX UC+CD 65 (49–80) 99 26
IFX UC 62 (29–95) 99 8
IFX CD 67 (59–75) 91 16
ADA UC+CD 63 (55–70) 0 5
ADA UC 58 (48–68) NA 1
ADA CD 69 (58–80) 0 4
Anti-TNF: anti-tumor necrosis factor. UC: ulcerative colitis. CD: Crohn’s disease. IFX: Infliximab. ADA: Adalimumab.
3.2.2. Remission Rate
The remission rates ranged from 17% (168) to 94% (183) in naïve patients and from
17% (60) to 85% (124) in non-naïve patients. The overall remission rate to empirical DI was
48% (95% CI: 39–58%, I2 = 92%, 25 studies) and 44% (95% CI: 17–71%, I2 = 95%, six studies)
in naïve and non-naïve patients, respectively (Figure 5). No significant differences were
found between the subgroups (p > 0.05).
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Table 5. Remission rate by the anti-TNF agent and medical condition in naïve patients.
Anti-TNF UC/CD Remission Rate(%, 95% CI) I2 (%)
Number of
Included Studies
IFX UC+CD 46 (34–59) 93 14
IFX UC 50 (25–74) 96 7
IFX CD 43 (33–53) 60 6
ADA UC+CD 44 (31–58) 86 10
ADA UC 17 (07–27) NA 1
ADA CD 50 (36–64) 79 8
Anti-TNF: anti-tumor necrosis factor. UC: ulcerative colitis. CD: Crohn’s disease. IFX: Infliximab. ADA: Adalimumab.
3.3. Pediatric Population
A total of 24 studies reported data on children (<18 years) (Table 1). When compared
to the adult population, no statistical differences were found in terms of the DI required or
its efficacy. The random-effects pooled DI rate in naïve patients after a 12-month follow-up
was 29% (95% CI 21–37%, I2 = 81%, n = 9).
3.4. Randomized Controlled Trials
A total of five randomized controlled trials (Table 1) assessed the DI requirements
after a 12-month follow-up in naïve patients. The random-effects pooled DI rate was 29%
(95% CI 18–41%. I2 = 88%, five studies). No statistical differences were found when this
subgroup was compared to the group of observational studies.
3.5. Sensitivity Analyses and Risk of Bias
We further investigated potential sources of heterogeneity by excluding studies that
included extreme or diverging values in certain subgroups, such as the DI requirements
after 12 months [34,100,123,127,147,165] and 36 months [85,113] of follow-up or the re-
sponse [147] and remission [61,145,168,183] rates. The effects of including different follow-
up periods in the same subgroup [34,147,149] or the use of different induction dosing regi-
mens [13,126,138] were also explored. In all cases, the results were stable, with no significant
variations after the sensitivity analysis, although the heterogeneity remained considerable.
Among the six RCTs evaluated for a potential risk of bias, five had a low risk of bias for
randomization, and four of them reported on the implementation of the random allocation
sequence preserving concealment. Four studies also reported the adequate blinding of
participants and personnel. Three studies showed low risks of attrition bias; in two of
them, the number of excluded patients was not specified, and in the remaining one, there
was a difference in the proportion of the outcome data. Finally, none of the studies was
considered to show reporting biases. In conclusion, for most of the RCT items assessed,
there was a low potential risk of bias detected.
4. Discussion
A LOR to the anti-TNF agents represents a therapeutic challenge to gastroenterologists,
as these drugs are usually indicated in severe forms of the disease, and the remaining
treatment options in such situations are limited. However, there is no unanimous definition
of LOR in the literature [185,186]; it has been defined as an increase in clinical activity
(which can be assessed by numerous activity indices) or, alternatively, as the need to modify
or discontinue the current treatment. Thus, several authors have proposed that the DI
requirement, which has been shown to recapture the response in multiple studies [187],
would be a more objective and reliable measure [188] and, therefore, a useful surrogate
for the LOR. Several reviews have previously assessed the incidence of a LOR, mainly in
CD [185–191]. When compared to previous reviews, our study includes a considerably
higher number of studies, up to January 2020, assessing both UC and CD patients and,
therefore, conferring more robustness and reliability to our work.
J. Clin. Med. 2021, 10, 2132 18 of 28
4.1. Prior Anti-TNF Exposure
Several studies have estimated that approximately one-third of inflammatory bowel
disease patients experience LOR and require DI, and that occurs more frequently in patients
with prior anti-TNF exposure [188–191].
In our study, the overall rate of the DI requirements at a one-year follow-up was 28%
in naïve and 39% in non-naïve patients, respectively. This shows no relevant differences
with the previous data and constitutes one main finding of our study: dose escalation was
needed more often in patients with prior anti-TNF use. In fact, the vast majority of the
included studies evaluating both naïve and non-naïve patients showed a greater incidence
in the loss of response in those non-naïve [30,34,35,60,81,84,111,121,132,161,163,168,192,193].
4.2. Time of Follow-Up
Additionally, the time course of LOR remains poorly understood. The median time
from the first anti-TNF exposure to the need for a DI varied widely among the studies,
from 2.7 to 18 months. However, there is increasing evidence showing that such events
occur mostly within the first year of anti-TNF therapy [186].
In our study, no differences were found in the rate of DI for the short term, 12 and
36 months of follow-up, supporting the fact that the LOR and consequent DI occur mainly
during the first year of treatment.
4.3. Medical Baseline Condition
Another relevant finding in our study was that a DI was required more frequently in
UC than in CD patients. Previous data indicated that some patients with active UC have
a higher inflammatory burden and accelerated anti-TNF clearance [194–196]; therefore,
they could require a higher drug exposure to achieve a response to TNF antagonists. This
could be the rational explanation UC patients need for an earlier and more frequent DI
than CD patients [110,120,167]. However, there is also evidence not supporting these
results [174]. Further research should be conducted, as no randomized trials have focused
on this subgroup of patients; they seem to have the highest DI rate and could benefit the
most from alternative treatment strategies.
4.4. Anti-TNF Agent
The comparison between the IFX and ADA DI rates is also a matter of interest. Im-
munogenicity is believed to be a common cause of LOR due to the formation of antidrug
antibodies. Some authors have argued that the chimeric nature of IFX, as opposed to
the fully humanized ADA, could render the former more prone to generate an antibody
response. However, in our study, we did not find significant differences in the DI rate
between IFX and ADA patients, as in previous comparative reports [115].
4.5. Dose Intensification Efficacy
Several clinical trials and open-label cohorts included in a previous review reported
DI to restore the response in 50–70% of patients [186]. Billioud et al. also found that DI
restored the response in 71% and remission in 40% of the patients [189].
In our study, the response and remission rates to empirical DI in naïve patients were
63% and 48%, respectively. Although no significant differences were reported between the
naïve and non-naïve patients, either in the response or remission rates, a trend towards a
reduced DI efficacy in the patients with prior anti-TNF exposure was shown.
Our findings support that using all the available treatment options with the first
anti-TNF agent through DI (even if it is not based on therapeutic drug monitoring) should
be considered before switching to another anti-TNF agent or to another therapeutic target.
Nevertheless, it should be noted that almost all studies do assess the DI efficacy in the short
term; additional research regarding the long-term response and remission rates after DI
should be performed.
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4.6. Limitations
Our study had some limitations. First of all, the DI can result in an equivocal interpre-
tation of the LOR if it is done without accurately confirming the disease activity. In addition,
there were also some possible predictors for the LOR or DI that were not evaluated in our
study, such as the concomitant use of immunomodulators. However, recent guidelines
(three) have suggested monotherapy with anti-TNF in patients with long-term remission
rather than the use of a combination therapy. Finally, we excluded studies in which the DI
was made based on therapeutic drug monitoring, with the aim to assess the effectiveness
of empirical DI. In this respect, the current guidelines (three) do not recommend either
proactive or reactive therapeutic drug monitoring as a standard clinical practice due to
insufficient evidence. Finally, we did not perform a quality assessment of all the included
studies given the high heterogeneity of the observational studies encountered in terms of
the design and number. It was decided to perform a risk of bias assessment exclusively
in RCTs, which represented no more than 1.5% of the total of patients included in our
systematic review but, including 512 patients, was a sufficient sample size to drawn robust
conclusions. In terms of quality, most studies showed a low risk of bias for the majority of
the items assessed, highlighting both an adequate random sequence generation and alloca-
tion concealment, as well as blinding: items that were usually preserved. Additionally, a
subgroup analysis was performed to control for heterogeneity in terms of study design,
and no significant differences in the DI requirement between the RCTs and observational
studies were reported.
5. Conclusions
A LOR to anti-TNF agents—and, consequently, DI—occurs frequently in inflammatory
bowel disease, with an overall rate of DI requirement of approximately one-fourth at one
year and one-third at three years. DI is required more frequently in patients with prior
exposure to anti-TNF agents and in UC patients. Empirical DI is a relatively effective
therapeutic option, achieving a response in two-thirds and remission in one-half of those
patients naïve to anti-TNF treatment.
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